Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;59(12):3106-3116.
doi: 10.1002/ppul.27190. Epub 2024 Jul 26.

Cystic fibrosis year in review 2023

David V Swetland  1   2 , Adrienne P Savant  1   2
Affiliations
Review

Cystic fibrosis year in review 2023

David V Swetland et al. Pediatr Pulmonol. 2024 Dec.

Abstract

This past year, there were many important advances for patients with cystic fibrosis (CF). Of the many publications related to CF in 2023, there was further evaluation of highly effective modulator therapy, new assessments and guidelines for clinical manifestations and therapies for CF, advances in newborn screening and diagnosis, and evaluation of outcomes for people with CF transmembrane conductance regulator-related metabolic syndrome/CF screen positive, inconclusive diagnosis. The aim of this review article is not to provide a full assessment of the wide range of articles published in 2023, but to provide a brief review of publication that may lead to changes in clinical care.

Keywords: CFTR modulators; cystic fibrosis; hepatobiliary; newborn screening; pulmonary exacerbations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Goralski JL, Hoppe JE, Mall MA, et al. Phase 3 open‐label clinical trial of elexacaftor/tezacaftor/ivacaftor in children aged 2‐5 years with cystic fibrosis and at least one F508del allele. Am J Respir Crit Care Med. 2023;208(1):59‐67. - PMC - PubMed
    1. Lebecque P, Thimmesch M, Meurrens J, Jeanmart P. Cystic fibrosis: does it matter to avoid crushing elexacaftor/tezacaftor/ivacaftor (ETI) tablets? Pediatr Pulmonol. 2023;58(12):3603‐3604. - PubMed
    1. Wainwright C, McColley SA, McNally P, et al. Long‐term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis and at least one F508del allele: a phase 3, open‐label clinical trial. Am J Respir Crit Care Med. 2023;208(1):68‐78. - PMC - PubMed
    1. Southern KW, Barben J, Goldring S, et al. Raised intracranial pressure in three children with cystic fibrosis receiving elexacaftor‐tezacaftor‐ivacaftor modulator therapy. Am J Respir Crit Care Med. 2023;208(1):103‐105. - PubMed
    1. Daines CL, Tullis E, Costa S, et al. Long‐term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144‐week interim results from a 192‐week open‐label extension study. Eur Respir J. 2023;62:2202029. - PMC - PubMed

MeSH terms

Substances

Grants and funding